Compare ATLC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLC | MPLT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2009 | 2025 |
| Metric | ATLC | MPLT |
|---|---|---|
| Price | $92.98 | $8.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $130.60 | $26.54 |
| AVG Volume (30 Days) | 89.0K | ★ 362.2K |
| Earning Date | 11-09-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.95 | ★ 82.39 |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $1,968,399,000.00 | N/A |
| Revenue This Year | $443.34 | N/A |
| Revenue Next Year | $14.01 | N/A |
| P/E Ratio | $19.36 | ★ N/A |
| Revenue Growth | ★ 50.09 | N/A |
| 52 Week Low | $47.50 | $8.92 |
| 52 Week High | $114.34 | $40.43 |
| Indicator | ATLC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 26.17 |
| Support Level | $91.00 | N/A |
| Resistance Level | $95.69 | $14.22 |
| Average True Range (ATR) | 3.12 | 0.61 |
| MACD | 0.55 | 0.02 |
| Stochastic Oscillator | 80.60 | 0.00 |
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.